Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CTLA4-Ig changed the gene expression associated with cellular movement in osteoclast precursors

ABSTRACT: CTLA4-Ig changed the gene expression associated with cellular movement in osteoclast precursors

PROVIDER: PRJNA449394 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6973810.fastq.gz	Fastqsanger.gz
	SRR6973811.fastq.gz	Fastqsanger.gz
	SRR6973806.fastq.gz	Fastqsanger.gz
	SRR6973807.fastq.gz	Fastqsanger.gz
	SRR6973808.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

CTLA4-Ig changed the gene expression associated with cellular movement in osteoclast precursors

Project description:To explore comprehensive gene expression changes, we performed an RNA sequence analysis of CX3CR1-EGFP+ cells from calvaria in mice treated with CTLA4-Ig or control IgG.

2018-05-06 | GSE112896 | GEO

Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig

Project description:During activation, T cells integrate multiple signals from APCs and cytokine milieu. The blockade of these signals can have clinical benefits as exemplified by CTLA4-Ig, which blocks interaction of B7 co-stimulatory molecules on APCs with CD28 on T cells. Variants of CTLA4-Ig, abatacept and belatacept are FDA approved as immunosuppressive agents in arthritis and transplantation whereas murine studies suggested that CTLA4-Ig can be beneficial in a number of other diseases. However, detailed analysis of human CD4 cell hyporesponsivness induced by CTLA4-Ig has not been performed. Herein, we established a model to study effect of CTLA4-Ig on the activation of human naM-CM-/ve T cells in a human mixed lymphocytes system. Comparison of human CD4 cells activated in the presence or absence of CTLA4-Ig, showed that co-stimulation blockade during TCR activation does not affect NFAT signaling but results in decreased activation of NF-kB and AP-1 transcription factors followed by profound decrease in proliferation and cytokine production. The resulting T cells become hyporesponsive to secondary activation and, although capable of receiving TCR signals, fail to proliferate or produce cytokines, demonstrating properties of anergic cells. However, unlike some models of T cell anergy, these cells did not possess increased levels of TCR signaling inhibitor CBLB. Rather, the CTLA4-Ig induced hyporesponsiveness was associated with an elevated level of p27kip1 cyclin-dependent kinase inhibitor. Time series. Human resting and activated T cell dUTP mRNA-Seq profiles were generated on Illumina HiSeq2500

2015-02-17 | E-GEOD-64712 | biostudies-arrayexpress

Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig

Project description:During activation, T cells integrate multiple signals from APCs and cytokine milieu. The blockade of these signals can have clinical benefits as exemplified by CTLA4-Ig, which blocks interaction of B7 co-stimulatory molecules on APCs with CD28 on T cells. Variants of CTLA4-Ig, abatacept and belatacept are FDA approved as immunosuppressive agents in arthritis and transplantation whereas murine studies suggested that CTLA4-Ig can be beneficial in a number of other diseases. However, detailed analysis of human CD4 cell hyporesponsivness induced by CTLA4-Ig has not been performed. Herein, we established a model to study effect of CTLA4-Ig on the activation of human naïve T cells in a human mixed lymphocytes system. Comparison of human CD4 cells activated in the presence or absence of CTLA4-Ig, showed that co-stimulation blockade during TCR activation does not affect NFAT signaling but results in decreased activation of NF-kB and AP-1 transcription factors followed by profound decrease in proliferation and cytokine production. The resulting T cells become hyporesponsive to secondary activation and, although capable of receiving TCR signals, fail to proliferate or produce cytokines, demonstrating properties of anergic cells. However, unlike some models of T cell anergy, these cells did not possess increased levels of TCR signaling inhibitor CBLB. Rather, the CTLA4-Ig induced hyporesponsiveness was associated with an elevated level of p27kip1 cyclin-dependent kinase inhibitor.

2015-02-17 | GSE64712 | GEO

Identification of candidate immunity biomarkers associated with age-related variations in osteoclast activity following orthodontic tooth movement

Project description:This study provides a comprehensive examination of the influence of age on osteoclast activity during orthodontic tooth movement, analyzed through the lens of osteoimmunology, identifying key immune molecules and cells involved in the regulation.We identified key molecules that play an important role in orthodontic bone reconstruction by analyzing the differences in immune inflammatory differential gene expression across different age groups. These molecules, which facilitate macrophage migration to the local site and their differentiation into osteoclasts, as well as directly enhance osteoclast differentiation and function, are differentially expressed in young groups, but not in adult groups.

2025-08-20 | GSE299315 | GEO

Innate immune activity differentiate subtypes in new onset Type 1 diabetes that predict duration of the post-onset partial remission and correlate with responsiveness to CTLA4-Ig treatment

Project description:New measures are needed to predict type 1 diabetes disease trajectory. We have developed a sensitive array-based bioassay whereby patient plasma is used to induce transcription in healthy “reporter” leukocytes. Here we report a refined gene ontology-based inflammatory index (I.I.359) that is based upon expression levels of 359 transcripts identified in cross-sectional studies of new onset Type 1 diabetes patients and controls, where higher scores reflect greater inflammatory bias. We examined the relationship between I.I.359 measured at onset and the post-onset disease course in local patients as well as participants of the TrialNet CTLA4-Ig trial. In untreated patients, I.I.359 at baseline was highly variable and exhibited a significant inverse relationship with stimulated C-peptide AUC at 3, 6, 12, 18 and 24 months post-onset. Further, duration of the post-onset partial remission was negatively related to baseline I.I.359 and positively associated with the peripheral abundance of activated regulatory T cells (CD4+/CD45RA-/FoxP3high).

2018-07-19 | GSE102234 | GEO

Expression data from Ctla4-/- and DKO CD4+ Tconv cells

Project description:Ctla4-/- mice suffer from a severe autoimmunity characterized by indiscriminate self-reactive T cell activation. Itk-/-Ctla4-/- (DKO) mice are protected from lethal autoimmunity despite a fulminant autoimmune process in the LNs as self-reative T cells fail to migrate to destroy tissues. We used microarray to identify underlying differences in gene expression that could account for lack of migration of DKO T cells into tissues. CD4+CD25neg T cells from 3 weeks old male Ctla4-/- or DKO mice were sorted in duplicates, RNA was extracted using TRIzol reagent and microarray analysis performed with the Affymetrix MoGene 1.0 ST array

2013-09-25 | E-GEOD-51099 | biostudies-arrayexpress

Identification of candidate immunity biomarkers associated with age-related variations in osteoclast activity following orthodontic tooth movement

Project description:Identification of candidate immunity biomarkers associated with age-related variations in osteoclast activity following orthodontic tooth movement

| PRJNA1273898 | ENA

Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy

Project description:The lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency causes severe autoimmune diseases and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) loss in humans. However, the impact of LRBA on antitumor immunity remains understudied. Here, we identified the role of LRBA in antitumor immunity and developed a novel immunotherapy for cancers. Interestingly, LRBA was negatively associated with antitumor immunity in human patients. Using high-throughput screening and subsequent structure-based hit optimization, we discovered a small molecule LC427 that bound directly to LRBA, and selectively interfered with the LRBA-CTLA4 interaction. This mechanistically unique LC427 facilitated the lysosomal degradation of CTLA4, and bolstered survival and functions of activated T cells. Importantly, orally administrated LC427 increased tumor-infiltrating CD8+ T cells and displayed effective antitumor activity in tumor-bearing mouse models. Notably, LC427 did not induce typical irAEs observed with immune checkpoint inhibitors in colitis models. Our study demonstrates that targeting LRBA offers a novel and effective strategy with a favorable safety profile, highlighting the potential of LRBA-based immunomodulatory therapies in the treatment of cancers.

2026-01-23 | PXD064363 | Pride

miR-155 role in osteoclast differentiation

Project description:We used microarrays to understand the effect miR-155 has on osteoclast differentiation. RAW264.7 cells were grown in a-MEM supplemented with 10% FBS and antibiotics. mRNA extracted from wild-type RAW264.7 cells and miR-155 mis-expressing cells either before or after 72 hr of stimulation with 20ng/ml RANKL and M-CSF to induce osteoclast differentiation.

2010-07-30 | E-GEOD-16749 | biostudies-arrayexpress

Expression data from Ctla4-/- and DKO CD4+ Tconv cells

2013-09-25 | GSE51099 | GEO